Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.

Authors

Christa Davis, Arun Vignesh, Sudha Rangarajan, Murugan Sundaram, Adikrishnan Swaminathan

Published in

Cureus. Volume 18. Issue 9. Pages e116921. Epub Sep 25, 2026.

Abstract

Sorafenib is an oral multikinase inhibitor approved for advanced hepatocellular carcinoma, renal cell carcinoma, and maintenance therapy in selected patients with FMS-like tyrosine kinase (FLT3)-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. We report the case of a 35-year-old woman with FLT3 internal tandem duplication (FLT3-ITD) and nucleophosmin 1 (NPM1)-positive acute myeloid leukemia (AML) who developed painful hyperkeratotic plantar plaques approximately eight weeks after initiating sorafenib therapy. Clinical examination revealed multiple symmetrical hyperkeratotic plaques involving the pressure-bearing areas of both soles, associated with pain and tenderness, resulting in significant impairment of daily activities. She was diagnosed with sorafenib-induced hand-foot skin reaction (HFSR) and was managed with topical keratolytic and corticosteroid therapy. This case highlights the importance of early recognition and prompt management of sorafenib-induced HFSRs to minimize morbidity and maintain oncological treatment.

PMID:
42928832
Bibliographic data and abstract were imported from PubMed on 26 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.